Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federa... (rves ongoing scrutiny Dr. Kim said. S...)

Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates

Date:11/6/2007

rves ongoing scrutiny, Dr. Kim said.

She suggests that educational efforts at the level of the patient, study site, and investigator are needed to increase participation of women. Additional research into why so few women participate in clinical trials is also warranted, she said.

Of the 982 NHLBI-funded cardiovascular studies examined, 141 were phase III or IV randomized controlled trials in adults, 53 had outcomes of interest, and only 19 were published between 1997 and 2006. The research spanned 19 trials: nine acute, eight high risk, eight coronary artery disease, three congestive heart failure and seven electrophysiology trials, in addition to one hypertension trial. Researchers observed no increase in the enrollment of women between 1997 and 2006 (mean 27%, range 10-47%). There was no association between enrollment and acuity, type of disease, or level of risk.

Cleveland Clinic, located in Cleveland, Ohio, is a not-for-profit multispecialty academic medical center that integrates clinical and hospital care with research and education. Cleveland Clinic was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. Approximately 1,800 full-time salaried physicians and researchers at Cleveland Clinic and Cleveland Clinic Florida represent more than 100 medical specialties and subspecialties. In 2006, there were 3.1 million outpatient visits to Cleveland Clinic. Patients came for treatment from every state and from more than 80 countries. There were more than 53,000 hospital admissions to Cleveland Clinic in 2006. Cleveland Clinic's Web site address is http://www.clevelandclinic.org.

SOURCE Cleveland Clinic
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
2. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
5. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
10. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
11. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy

Post Your Comments:

(Date:5/24/2013)... , May 24, 2013 Solta Medical, Inc. (NASDAQ: ... aesthetics market, today reported Dr. Edward W. Knowlton ... Board of Directors effective immediately. Dr. Knowlton is the founder ... served as a director since 1996. "On behalf ... management team, I would like to thank Ed for his ...

(Date:5/24/2013)... An international roster of experts on malignant pleural ... Santa Monica, Calif. , to discuss their ... a rare form of cancer that results from exposure ... of the chest. Hosted by UCLA and ... Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural ...

(Date:5/24/2013)... Colo. , May 24, 2013 Heska Corporation (NASDAQ: ... diagnostic and specialty products, announced today that Dr. ... officer, and Jason Napolitano , executive vice ... Annual Marcum MicroCap Conference, which is being held May 30, ... the Grand Hyatt Hotel. The Company,s presentation ...

Breaking Medicine Technology:Dr. Edward W. Knowlton Resigns as a Director of Solta Medical, Inc. 2 International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2 International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3 Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2

[0] Dr. Edward W. Knowlton Resigns as a Director of Solta Medical, Inc.[0] International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma [0] Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference

... & MENLO PARK, Calif.--(BUSINESS WIRE)--Jun,4, 2007 - ... the presentation of data from its Quinamed(R),(amonafide ... a genotypically optimised dose of Quinamed in,heavily ... tumors. The,key outcomes from this study were ...

... in Journal Heart Finds Taxus Stent,Implantation of Multiple Stents ... for Another Procedure, , MIAMI LAKES, Fla., ... analysis of data from the Western Denmark Heart,Registry found ... open a clogged artery were less,likely to need another ...

Cached Medicine Technology:ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 2 ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 3 ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 4 New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World Clinical Settings 2 New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World Clinical Settings 3

ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World Clinical Settings

(Date:5/24/2013)... Paris, France: Routinely measuring fractional flow reserve (FFR) ... diagnosis of chest pain leads to significant changes ... according to results from a study reported at ... wire assessment influence management strategy at coronary angiography ... to assess whether routine assessment of FFR in ...

(Date:5/24/2013)... new investigational device - the Helio System (TF-FA) - ... Heart Valve was successfully deployed in all four patients ... in high-risk aortic insufficiency reported at EuroPCR 2013. , ... help stabilise the SAPIEN XT valve for patients with ... captured between the transcatheter heart valve and the dock. ...

(Date:5/24/2013)... valve implantation (TAVI) is effective and safe in Asian ... from a multicentre Asian registry reported at EuroPCR 2013. ... treatment option for selected patients with symptomatic severe aortic ... American or European centres," Paul Chiam, senior consultant cardiologist ... He explained that it is unknown whether the smaller ...

(Date:5/24/2013)... news about youth and diabetes keeps getting worse. The latest ... who develop Type 2 diabetes are at high risk to ... higher rate than people who acquire Type 2 diabetes as ... they seem to be at very high risk for early ... of pediatric endocrinology in the School of Medicine at The ...

(Date:5/24/2013)... discovery at Oregon Health & Science University highlights an ... infected with the highly evasive HIV virus that causes ... this unique approach to develop its own HIV vaccine ... animal studies. This latest research finding will be published ... Science . , "A major challenge in ...

Breaking Medicine News(10 mins):Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2 Health News:Feasibility trial reports deployment of new device for TAVI in aortic insufficiency 2 Health News:Registry confirms TAVI efficacy and safety in Asian patients 2 Health News:Youth with type 2 diabetes at much higher risk for heart, kidney disease 2 Health News:OHSU research highlights promising strategy to help vaccines outsmart HIV 2

[0] Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases [0] Feasibility trial reports deployment of new device for TAVI in aortic insufficiency [0] Registry confirms TAVI efficacy and safety in Asian patients [0] Youth with type 2 diabetes at much higher risk for heart, kidney disease [0] OHSU research highlights promising strategy to help vaccines outsmart HIV

... million, up 7.6% from the first ... quarter of 2007., - Same ... March 31, 2008 over the corresponding period ended in 2007.,- Cash From Facility ... 19% increase over the first period of 2007, and was $0.41 per ...

... drugs that work by blocking brain molecules similar to ... in young children, according to a new study from ... is known to be an appetite stimulant, and a ... Acomplia) developed by Sanofi-Aventis and awaiting approval for use ...

... The American Academy,of Physician Assistants (AAPA), representing ... U.S., is pleased to join other national,organizations ... Treating Tobacco Use and Dependence: 2008 Update., ... even stronger,evidence to support the efforts of ...

... SAO PAULO, Brazil, May 7 Medial Saude S/A,(BOVESPA: MEDI3) (MEDIAL SAUDE) announces the following webcast:, ... When: Thursday, May 8, 2008 @ 12:00 PM EDT, Where: ... Internet -- Simply log on to the web at the ... Conference call dial-in phone numbers: ...

... a Puzzling Pediatric Tumor--, PHILADELPHIA, May 7 ... for the,first time identified a chromosome region that is ... an often fatal childhood cancer., The investigators found ... of chromosome 6 raises the risk that a child ...

... French . , Ottawa (May 7, 2008) ... today funding from the Canadian Institutes of Health Research ... over $298 million. Minister Clement was joined by Dr. ... Po-Yin Cheung, a neonatologist and CIHR-funded researcher from the ...

Brookdale Announces First Quarter 2008 Results MIT study suggests caution on new anti-obesity drug in kids AAPA Endorses 2008 Public Health Service Guidelines for Treating Tobacco Use and Dependence Webcast Alert: Medial Saude S/A Announces First Quarter 2008 Earnings Conference Call Webcast Researchers Find Gene Location That Gives Rise to Neuroblastoma, an Aggressive Childhood Cancer CIHR news: health research touching lives

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

T-Cell Immunodeficiency Extended Profile T-Cell Clonality Assessment by Restriction Fragment Southern Blot Hybridization, Fluid Syphilis Antibody, IgM by ELISA Susceptibility